Stock Track | Iovance Biotherapeutics Plunges 5.19% Pre-market Following Chardan's Price Target Cut

Stock Track11-07

Shares of Iovance Biotherapeutics, Inc. (IOVA) tumbled 5.19% in pre-market trading on Friday after Chardan Capital Markets lowered its price target on the stock. The significant downward adjustment in the price target appears to have sparked investor concerns, leading to the sharp decline in IOVA's stock price.

Chardan reduced its price target for Iovance Biotherapeutics from $20 to $17, representing a 15% decrease. This adjustment comes amid a broader analyst consensus that remains cautiously optimistic about the company. According to FactSet, the average analyst rating for IOVA is "overweight," with a mean price target of $7.75. The disparity between Chardan's new target and the average target suggests a wide range of opinions among analysts regarding the company's future prospects.

Despite the price target reduction, Chardan maintained its "Buy" rating on Iovance Biotherapeutics. This maintained positive outlook, coupled with the higher-than-average price target, indicates that Chardan still sees potential upside for the stock. However, the pre-market plunge suggests that investors are focusing more on the near-term implications of the lowered price target rather than the maintained bullish stance. As the market opens, it remains to be seen how this news will impact IOVA's trading throughout the regular session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158373670?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158373670","market":"hk","top_or_hot":-1,"title":"Stock Track | Iovance Biotherapeutics Plunges 5.19% Pre-market Following Chardan's Price Target Cut","media":"Stock Track","content":"<p>Shares of Iovance Biotherapeutics, Inc. (IOVA) tumbled 5.19% in pre-market trading on Friday after Chardan Capital Markets lowered its price target on the stock. The significant downward adjustment in the price target appears to have sparked investor concerns, leading to the sharp decline in IOVA's stock price.</p>\n\n<p>Chardan reduced its price target for Iovance Biotherapeutics from $20 to $17, representing a 15% decrease. This adjustment comes amid a broader analyst consensus that remains cautiously optimistic about the company. According to FactSet, the average analyst rating for IOVA is \"overweight,\" with a mean price target of $7.75. The disparity between Chardan's new target and the average target suggests a wide range of opinions among analysts regarding the company's future prospects.</p>\n\n<p>Despite the price target reduction, Chardan maintained its \"Buy\" rating on Iovance Biotherapeutics. This maintained positive outlook, coupled with the higher-than-average price target, indicates that Chardan still sees potential upside for the stock. However, the pre-market plunge suggests that investors are focusing more on the near-term implications of the lowered price target rather than the maintained bullish stance. As the market opens, it remains to be seen how this news will impact IOVA's trading throughout the regular session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Iovance Biotherapeutics Plunges 5.19% Pre-market Following Chardan's Price Target Cut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Iovance Biotherapeutics Plunges 5.19% Pre-market Following Chardan's Price Target Cut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Iovance Biotherapeutics, Inc. (IOVA) tumbled 5.19% in pre-market trading on Friday after Chardan Capital Markets lowered its price target on the stock. The significant downward adjustment in the price target appears to have sparked investor concerns, leading to the sharp decline in IOVA's stock price.</p>\n\n<p>Chardan reduced its price target for Iovance Biotherapeutics from $20 to $17, representing a 15% decrease. This adjustment comes amid a broader analyst consensus that remains cautiously optimistic about the company. According to FactSet, the average analyst rating for IOVA is \"overweight,\" with a mean price target of $7.75. The disparity between Chardan's new target and the average target suggests a wide range of opinions among analysts regarding the company's future prospects.</p>\n\n<p>Despite the price target reduction, Chardan maintained its \"Buy\" rating on Iovance Biotherapeutics. This maintained positive outlook, coupled with the higher-than-average price target, indicates that Chardan still sees potential upside for the stock. However, the pre-market plunge suggests that investors are focusing more on the near-term implications of the lowered price target rather than the maintained bullish stance. As the market opens, it remains to be seen how this news will impact IOVA's trading throughout the regular session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1158373670","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158373670","pubTimestamp":1762520577,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Iovance Biotherapeutics, Inc. (IOVA) tumbled 5.19% in pre-market trading on Friday after Chardan Capital Markets lowered its price target on the stock. The significant downward adjustment...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"个股追踪|Chardan下调目标价后Iovance Biotherapeutics盘前暴跌5.19%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"Shares of Iovance Biotherapeutics, Inc. (IOVA) tumbled 5.19% in pre-market trading on Friday after Chardan Capital Markets lowered its price target on the stock. The significant downward adjustment in the price target appears to have sparked investor concerns, leading to the sharp decline in IOVA's stock price.\nChardan reduced its price target for Iovance Biotherapeutics from $20 to $17, representing a 15% decrease. This adjustment comes amid a broader analyst consensus that remains cautiously optimistic about the company. According to FactSet, the average analyst rating for IOVA is \"overweight,\" with a mean price target of $7.75. The disparity between Chardan's new target and the average target suggests a wide range of opinions among analysts regarding the company's future prospects.\nDespite the price target reduction, Chardan maintained its \"Buy\" rating on Iovance Biotherapeutics. This maintained positive outlook, coupled with the higher-than-average price target, indicates that Chardan still sees potential upside for the stock. However, the pre-market plunge suggests that investors are focusing more on the near-term implications of the lowered price target rather than the maintained bullish stance. As the market opens, it remains to be seen how this news will impact IOVA's trading throughout the regular session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158373670","isCrawlerRequest":true}